secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entera Bio Ltd. (ENTXW)
CIK:        0001638097
Form:       8-K
Filed at:   2026-02-09T23:59:59+00:00
Accession:  0001178913-26-000355
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entera Bio appoints former Pfizer exec Geno J. Germano as Chairman, replacing Gerald Lieberman
--------------------------------------------------------------------------------

- Geno Germano appointed Class III director and Chairman of the Board effective February 4, 2026.
- Gerald Lieberman resigned as Chairman and Director effective Feb 4, 2026, no disagreement.
- Germano led Pfizer's $14B Global Innovative Pharma business as Group President until 2016.
- Entera plans Phase 3 registrational study for EB613 (osteoporosis) and first-in-human for Long-Acting Oral PTH (hypoparathyroidism) in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638097/000117891326000355/0001178913-26-000355-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638097/000117891326000355/zk2634303.htm
  HTML page:      https://secwatch.observer/filing/0001178913-26-000355

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer